NEW YORK (GenomeWeb) – BG Medicine today reported a 41 percent decline year over year in its first quarter revenues. 

For the three months ended March 31, the Waltham, Massachusetts-based firm said that revenues totaled $437,000, down from $739,000 in Q1 2014. BG Medicine said that the drop resulted from a decline in orders from its largest clinical laboratory customer. 

Net loss for the recently completed quarter narrowed to $1.3 million, or $.04 per share, compared to a net loss of $2.2 million, or $.08 per share, in Q1 2014.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.